Pharma & Biotech
An industry driven first by quality and regulatory compliance. Here the hazard is not explosion but the non-conforming product: an out-of-spec batch, an altered record, a contamination. Good manufacturing practice, data integrity and computerized system validation shape every piece of automation.
The main families
Synthesis or bioproduction
Synthetic chemistry or biological route. Often batch process, recipes, full batch genealogy traceability.
Formulation & sterile fill-finish
Tablets, injectables, aseptic fill. Cleanrooms, contamination control, packaging and serialization.
Cell culture & purification
Fermentation, bioreactors, downstream purification, single-use systems, cold chain.
Key challenges
- GMP & inspections — good manufacturing practice audited by the FDA and EMA. EU GMP Annex 1 covers sterile, Annex 11 computerized systems.
- Data integrity (ALCOA+) — every record must be attributable, legible, contemporaneous, original, accurate. Audit trails, 21 CFR Part 11 on the FDA side.
- Validation (CSV / GAMP 5) — every computerized system is validated to the V-model: IQ, OQ, PQ qualifications. ISPE's GAMP 5 framework.
- Sterility & contamination — ISO 14644-classified cleanrooms, environmental monitoring, aseptic design, bioburden control.
- Serialization & traceability — anti-counterfeiting: EU FMD directive, US DSCSA, GS1 unique identifiers on every pack.
Key technologies
Standards & references
The pharmaceutical framework relies mostly on its own references: EU GMP (Annexes 1 and 11), 21 CFR Part 11 (FDA), GAMP 5 (ISPE), the ICH guidelines (Q7, Q9, Q10), ISO 14644 for cleanrooms. The automation standards below structure production.
Major players
Pharma companies
Pfizer, Roche, Novartis, Merck (MSD), Sanofi, GSK, AstraZeneca, Novo Nordisk.
Contract manufacturing (CDMO)
Lonza, Samsung Biologics, Catalent, Thermo Fisher (Patheon), WuXi.
Automation & MES
Siemens (PCS neo, SIPAT), Emerson (DeltaV, Syncade), Rockwell (PharmaSuite), Körber (Werum PAS-X).
Bioprocess & equipment
Sartorius, Cytiva, Thermo Fisher, Eppendorf, GEA, Bosch (Syntegon).
Landmark cases
In pharma the lessons come not from explosions but from quality, integrity or sterility failures — each one tightened regulation.
| Case | Year | Theme | Lesson |
|---|---|---|---|
| Heparin contamination | 2008 | Supply chain | Contaminated heparin (oversulfated chondroitin) from a supplier; dozens of US deaths. Tightened control of raw materials and contractors. |
| Ranbaxy | 2013 | Data integrity | Fabricated data at Indian sites; $500M settlement with the FDA. Founding case of strict data-integrity enforcement (ALCOA+). |
| NECC | 2012 | Sterility | Contaminated injectables from a compounder; fungal meningitis, 60+ deaths. Led to the US compounding reform (DQSA 2013). |